Vaximm Strengthens Leadership with Appointment of Sébastien Wieckowski as Chief Scientific Officer

Vaximm Appoints Sébastien Wieckowski as Chief Scientific Officer

Vaximm AG, a subsidiary of OSR Holdings, has made a significant move in its leadership by appointing Dr. Sébastien Wieckowski as Chief Scientific Officer (CSO). This strategic decision aims to enhance its next-generation oral immunotherapy platform focuses on transforming cancer treatment options.

Dr. Wieckowski brings with him a wealth of experience in immunology and advanced data science, making him the perfect fit for a role that integrates analytical workflows and data-driven strategies within Vaximm's core technology. His expertise is expected to accelerate discoveries, optimize platform capabilities, and ultimately expedite the development of new therapies.

CEO Dr. Andreas Niethammer expressed enthusiasm about Dr. Wieckowski's appointment, citing their collaborative history since 2016. He noted that Dr. Wieckowski's profound understanding of Vaximm's oral vector technology has already led to substantial contributions, characterized by an impressive mix of strategic insight and practical execution.

The timing of this appointment is critical as Vaximm advances its lead candidate, VXM01, into more advanced stages of clinical trials while also exploring additional targets in the oncology landscape. As CSO, Dr. Wieckowski will spearhead strategic improvements to enhance the VXM platform, building on its existing strengths to broaden its capabilities further.

In an official statement, Dr. Constance Höfer, CSO of OSR Holdings, emphasized Dr. Wieckowski's integral role in Vaximm's research and development strategy, particularly regarding the oncology-focused candidate, VXM01. She asserted that his leadership will ensure a rigorous, data-led evolution of the core platform, paving the way for expanding its reach into a wider array of oncology and potentially non-oncology indications. This strategic alignment is crucial for OSR Holdings as it aims to transition platform-driven assets toward advanced partnerships.

Reflecting on his appointment, Dr. Wieckowski expressed his fulfillment in helping shape Vaximm’s journey. He stated, “Having been part of Vaximm’s development from its initial academic phases to the industrialization of our core assets, I am honored to step into the role of Chief Scientific Officer.” He conveyed a commitment to blending a deep knowledge of immunology with sophisticated data science techniques to revolutionize therapeutic approaches.

Dr. Wieckowski's vision focuses on fostering frameworks that support next-generation research, highlighting the importance of delivering therapies that prioritize precision, scalability, and patient-centered outcomes. His dedication ensures that the development of transformative treatments will be both rigorous and innovative, maintaining high standards of safety and efficacy.

As Vaximm AG continues to emerge as a pioneer in oral T-cell immunotherapy, the appointment of Dr. Wieckowski is a testament to its mission of advancing treatment possibilities through scientifically sound and data-integrated methodologies. The future of cancer treatment may very well hinge on the advancements spearheaded by Vaximm under his leadership.

Vaximm AG is dedicated to making significant strides in the biotechnology field, leveraging innovative approaches to immunotherapy to confront cancer more effectively, and Dr. Wieckowski’s expertise will play a pivotal role in this ongoing journey.

About Vaximm AG

Vaximm is a privately held biotechnology firm located in Switzerland and Germany, specializing in oral T-cell immunotherapy. Its flagship candidate, VXM01, demonstrates promising clinical efficacy and safety across multiple cancer types. Driven by a commitment to innovating in medical science, Vaximm aims to redefine how cancers are treated globally.

About OSR Holdings, Inc.

OSR Holdings, Inc., publicly traded on NASDAQ as OSRH, supports advancements in health and wellness through biotechnology, regenerative medicine, and medical devices aimed at improving global health outcomes. Learn more at OSR Holdings.